These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28161667)

  • 1. Aerodynamic properties and in silico deposition of meloxicam potassium incorporated in a carrier-free DPI pulmonary system.
    Chvatal A; Farkas Á; Balásházy I; Szabó-Révész P; Ambrus R
    Int J Pharm; 2017 Mar; 520(1-2):70-78. PubMed ID: 28161667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties.
    Ambrus R; Benke E; Farkas Á; Balásházy I; Szabó-Révész P
    Eur J Pharm Sci; 2018 Oct; 123():20-27. PubMed ID: 30016647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Stability testing of meloxicam-containing microcomposites for inhalation].
    Pomázi A; Ambrus R; Szabóné Révész P
    Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability test of novel combined formulated dry powder inhalation system containing antibiotic: physical characterization and
    Benke E; Farkas Á; Balásházy I; Szabó-Révész P; Ambrus R
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1369-1378. PubMed ID: 31096805
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of extra-fine particles containing nanosized meloxicam for deep pulmonary delivery: In vitro aerodynamic and cell line measurements.
    Party P; Kókai D; Burián K; Nagy A; Hopp B; Ambrus R
    Eur J Pharm Sci; 2022 Sep; 176():106247. PubMed ID: 35760279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery.
    Chvatal A; Ambrus R; Party P; Katona G; Jójárt-Laczkovich O; Szabó-Révész P; Fattal E; Tsapis N
    Int J Pharm; 2019 Mar; 559():68-75. PubMed ID: 30677482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an Innovative, Carrier-Based Dry Powder Inhalation Formulation Containing Spray-Dried Meloxicam Potassium to Improve the In Vitro and In Silico Aerodynamic Properties.
    Benke E; Farkas Á; Szabó-Révész P; Ambrus R
    Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32532040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and In Vitro and In Silico Characterization of "Nano-in-Micro" Dry Powder Inhalers Containing Meloxicam.
    Party P; Bartos C; Farkas Á; Szabó-Révész P; Ambrus R
    Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33546452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil.
    Nguyen TT; Yi EJ; Hwang KM; Cho CH; Park CW; Kim JY; Rhee YS; Park ES
    Drug Deliv Transl Res; 2019 Feb; 9(1):319-333. PubMed ID: 30276666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
    Agarwal V; Alayoubi A; Siddiqui A; Nazzal S
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1681-9. PubMed ID: 23072611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.
    Kaewjan K; Srichana T
    Pharm Dev Technol; 2016; 21(1):68-75. PubMed ID: 25331092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
    Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
    Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-based particle engineering via spray-drying for targeted delivery of antibiotics to the lung.
    Corzo C; Crvenjak D; Sotirov K; Afonso Urich J; Öhlinger K; Meindl C; Lochmann D; Reyer S; Fröhlich E; Zimmer A; Salar-Behzadi S
    Int J Pharm; 2023 Jul; 642():123201. PubMed ID: 37406948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry powder inhaler formulation comparison: Study of the role of particle deposition pattern and dissolution.
    Noriega-Fernandes B; Malmlöf M; Nowenwik M; Gerde P; Corvo ML; Costa E
    Int J Pharm; 2021 Sep; 607():121025. PubMed ID: 34418472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
    Yu H; Teo J; Chew JW; Hadinoto K
    Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
    Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
    Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new respirable form of rifampicin.
    Son YJ; McConville JT
    Eur J Pharm Biopharm; 2011 Aug; 78(3):366-76. PubMed ID: 21324356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Composition and Spray-Drying Process Parameters on Carrier-Free DPI Properties and Behaviors in the Lung: A review.
    Lechanteur A; Evrard B
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31936628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.